Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil extension study in cGVHD
NCT05305989Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Started Feb 2022; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05305989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305989.